Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial
The SOUL trial demonstrated that in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), the oral GLP-1 receptor agonist semaglutide significantly reduced the risk of cardiovascular events compared with placebo. This effect was consistent regardless of baseline use of SGLT2 inhibitors, according to a study presented by Dr. Darren K. McGuire, University of Texas Southwestern Medical Center, USA, in the Late-Breaking Clinical Trials session at ACC.25.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
